
BTIG raises Cullinan Therapeutics price target to $40 after positive lung cancer trial results
BTIG increased its price target for Cullinan Therapeutics to $40, reflecting a potential 93% upside from the current stock price of around $20.73. This upgrade follows successful Phase 3 trial results for zipalertinib, a treatment for non-small cell ...





